Analyst Price Target is $43.25
▲ +29.65% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for GSK in the last 3 months. The average price target is $43.25, with a high forecast of $47.00 and a low forecast of $39.50. The average price target represents a 29.65% upside from the last price of $33.36.
Current Consensus is
Moderate Buy
The current consensus among 10 contributing investment analysts is to moderate buy stock in GSK. This rating has held steady since August 2024, when it changed from a Buy consensus rating.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Read More
